Adults with type 1 diabetes receiving tirzepatide off-label had a similar rate of new-onset diabetic retinopathy compared with controls not using the drug, according to a chart review published in Diabetes Technology & Therapeutics.
Satish K. Garg, MD, professor of medicine and pediatrics at the Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, said there has been interest in assessing the impact incretin-based medications have on eye disease ever since the SUSTAIN-6 trial found semaglutide (Ozempic, Novo Nordisk) was associated with increased risk for